These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 32947554)
1. Oseltamivir-Current Dosing Recommendations Reduce the Therapeutic Benefit in Patients With Mild to Moderate Renal Function and/or Large Body Mass: A Review of the Literature With Recommendations to Optimize Dosing, Including the Use of Therapeutic Drug Monitoring. Jones TE Ther Drug Monit; 2021 Feb; 43(1):103-107. PubMed ID: 32947554 [TBL] [Abstract][Full Text] [Related]
2. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment. Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141 [TBL] [Abstract][Full Text] [Related]
3. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment. Gibiansky L; Giraudon M; Rayner CR; Brennan BJ; Subramoney V; Robson R; Kamal MA J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):225-36. PubMed ID: 25821064 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Davies BE J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135 [TBL] [Abstract][Full Text] [Related]
6. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Pai MP; Lodise TP Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881 [TBL] [Abstract][Full Text] [Related]
7. A part-randomized study of intravenous oseltamivir in adolescents and adults. Várkonyi I; Chappey C; Giraudon M; Burleigh L Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009 [TBL] [Abstract][Full Text] [Related]
8. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Ariano RE; Sitar DS; Zelenitsky SA; Zarychanski R; Pisipati A; Ahern S; Kanji S; Rello J; Kumar A CMAJ; 2010 Mar; 182(4):357-63. PubMed ID: 20159892 [TBL] [Abstract][Full Text] [Related]
9. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309 [TBL] [Abstract][Full Text] [Related]
10. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach. Kamal MA; Lien KY; Robson R; Subramoney V; Clinch B; Rayner CR; Gibiansky L Antimicrob Agents Chemother; 2015 Nov; 59(11):6774-81. PubMed ID: 26282419 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833 [TBL] [Abstract][Full Text] [Related]
12. Oseltamivir for treatment and prophylaxis of influenza infection. Schirmer P; Holodniy M Expert Opin Drug Saf; 2009 May; 8(3):357-71. PubMed ID: 19355841 [TBL] [Abstract][Full Text] [Related]
13. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Toovey S; Rayner C; Prinssen E; Chu T; Donner B; Thakrar B; Dutkowski R; Hoffmann G; Breidenbach A; Lindemann L; Carey E; Boak L; Gieschke R; Sacks S; Solsky J; Small I; Reddy D Drug Saf; 2008; 31(12):1097-114. PubMed ID: 19026027 [TBL] [Abstract][Full Text] [Related]
14. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Heneghan CJ; Onakpoya I; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Mahtani KR; Nunan D; Howick J; Jefferson T Health Technol Assess; 2016 May; 20(42):1-242. PubMed ID: 27246259 [TBL] [Abstract][Full Text] [Related]
16. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. Karsch K; Chen X; Miera O; Peters B; Obermeier P; Francis RC; Amann V; Duwe S; Fraaij P; Heider A; de Zwart M; Berger F; Osterhaus A; Schweiger B; Rath B Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):155-164. PubMed ID: 26994602 [TBL] [Abstract][Full Text] [Related]
19. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114 [TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]